BioStock Investor Meeting: Intervju med Pharmiva

AcouSort to present its unique acoustofluidics technology at the international conference µTAS 2023

AcouSort’s technology makes it possible to fractionate the different cell types in a blood sample, isolate extracellular vesicles, or wash cells to remove contaminants, without having any physical contact with the sample. The technology continues to find its way into an increasing number of life sci...

AcouSort presenterar sin unika teknologi för akusto-fluidik den internationella konferensen μTAS 2023

AcouSorts teknologi gör det möjligt att fraktionera de olika celltyperna i ett blodprov, isolera extracellulära vesiklar eller tvätta celler för att avlägsna föroreningar utan fysisk kontakt med provet. Teknologin fortsätter att finna en plats i allt fler life science-tillämpningar. Den 15-19 oktobe...

Brain+ A/S announces the exercise price for its warrants of series TO 2

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICA...

Annexin announces success in the company's cancer initiative

Within the framework of Annexin's cancer initiative, the company has successfully produced a so-called conjugate where the drug candidate ANXV is chemically bound to a chemotherapy agent and together forms a new composite molecule. In cell systems outside the body, this ANXV conjugate has been shown...